País: Canadá
Língua: inglês
Origem: Health Canada
IBUPROFEN
CUMBERLAND PHARMACEUTICALS INC
M01AE01
IBUPROFEN
100MG
SOLUTION
IBUPROFEN 100MG
INTRAVENOUS
250ML
Prescription
OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS
Active ingredient group (AIG) number: 0108883008; AHFS:
APPROVED
2019-09-11
_Caldolor_ _® _ _Product Monograph _ _Page 1 of 31_ PRODUCT MONOGRAPH PR CALDOLOR ® Ibuprofen for Intravenous Injection 100 mg/mL Nonselective Cyclooxygenase Inhibitor Nonsteroidal Anti-Inflammatory Drug (NSAID) Alveda Pharmaceuticals Inc 40 Holly Street, Suite 801 Toronto ON M4S 3C3 DATE OF PREPARATION: MAY 14, 2012 SUBMISSION CONTROL NO: 147713 _Caldolor_ _® _ _Product Monograph _ _Page 2 of 31 _ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION..........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 INDICATIONS AND CLINICAL USE..............................................................................3 CONTRAINDICATIONS ...................................................................................................3 WARNINGS AND PRECAUTIONS..................................................................................4 ADVERSE REACTIONS..................................................................................................11 DRUG INTERACTIONS ..................................................................................................14 DOSAGE AND ADMINISTRATION..............................................................................16 OVERDOSAGE ................................................................................................................17 ACTION AND CLINICAL PHARMACOLOGY ............................................................18 STORAGE AND STABILITY..........................................................................................19 DOSAGE FORMS, COMPOSITION AND PACKAGING .............................................19 PART II: SCIENTIFIC INFORMATION ...............................................................................21 PHARMACEUTICAL INFORMATION..........................................................................21 CLINICAL TRIALS.......................................................................................... Leia o documento completo